Charles Schwab Investment Management Inc. Purchases 10,542 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Charles Schwab Investment Management Inc. lifted its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 1.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 635,494 shares of the company’s stock after purchasing an additional 10,542 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Kura Oncology were worth $5,535,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of KURA. China Universal Asset Management Co. Ltd. lifted its position in shares of Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after purchasing an additional 1,750 shares during the period. Point72 DIFC Ltd bought a new position in Kura Oncology in the third quarter worth about $146,000. US Bancorp DE raised its stake in Kura Oncology by 184.5% in the fourth quarter. US Bancorp DE now owns 22,104 shares of the company’s stock worth $193,000 after buying an additional 14,335 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in Kura Oncology in the third quarter worth about $215,000. Finally, Bellevue Group AG boosted its position in Kura Oncology by 36.0% during the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after acquiring an additional 3,600 shares in the last quarter.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock worth $92,307 over the last three months. 5.50% of the stock is currently owned by company insiders.

Kura Oncology Stock Down 6.9 %

KURA stock opened at $7.12 on Wednesday. The stock has a market capitalization of $574.98 million, a P/E ratio of -3.02 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology, Inc. has a 1-year low of $6.79 and a 1-year high of $23.48. The business has a fifty day moving average price of $7.83 and a 200-day moving average price of $12.21.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. Equities analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on KURA shares. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. Scotiabank decreased their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, UBS Group cut their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.